Diamond Hill Capital, an investment management company, released its “Select Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here. The portfolio appreciated double digits in Q1 outperforming the Russell 3000 Index. The strategy returned 12.66% gross of fees and 12.43% net of fees vs 10.02% for the index. The relative […]
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.